GILD Gilead Sciences Inc

Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were two incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group. Twice-yearly lenacapavir also demonstrated sup

FOSTER CITY, Calif. & BURLINGAME, Calif., September 10, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.